Michael Feld, Executive Vice President of Becton Dickinson & Co (NYSE: BDX), disposed of 75 shares of common stock on January 26, 2026, at a per-share price of $202.73. The transaction generated proceeds of $15,204 and, after the sale, Feld directly held 16,431 shares of the company.
The sale was carried out pursuant to a Rule 10b5-1 trading plan that Feld adopted on February 7, 2025. The paperwork for the January 26 trade was signed on January 28, 2026, by Donna Kalazdy under a power of attorney on Feld's behalf.
Company updates and operational moves
Alongside the insider transaction disclosure, Becton, Dickinson and Company announced several corporate actions and product developments. The board declared a quarterly dividend of $1.05 per share, with payment scheduled for March 2026. The company also authorized a repurchase program that could cover as many as 10 million shares.
BD reported shareholder backing for a strategic deal as well: holders of Waters Corporation approved the combination with BD’s Biosciences & Diagnostic Solutions business, with 99% voting in favor. The company also introduced BD® Research Cloud 7.0, described as an AI-powered tool designed to support scientific workflows by optimizing panel design for flow cytometry research.
In product and partnership news, BD is working with Ypsomed to develop a 5.5 mL prefillable syringe that will be compatible with the YpsoMate 5.5 autoinjector platform, a solution targeted at administering large-volume biologic therapies. Separately, BD received FDA clearance for the EnCor EnCompass Breast Biopsy and Tissue Removal System, which the company expects to make available in early 2026.
Context and factual limits
The transaction details presented here are limited to the public disclosures: share count sold, sale price, total value, remaining direct holdings, the 10b5-1 adoption date, and the signature by power of attorney. The company developments listed are those explicitly reported in the disclosure and include dividend timing and amount, the authorized share repurchase quantity, the Waters shareholder vote percentage, the launch of the BD Research Cloud 7.0 product, the Ypsomed collaboration on a 5.5 mL syringe, and FDA clearance for the EnCor EnCompass system. No additional financial metrics, motivations for the insider sale, or forward-looking outcomes are provided in the disclosure.
Impacted sectors - The information touches healthcare and medical technology sectors, with potential relevance to capital markets because of the dividend and buyback authorization, and to clinical and research communities because of the product launches and AI research tools.